Mikhail Blagosklonny is a Russian professor, physician, and scientist well versed in matters relating to cancer treatments and reversing the aging process. Some of the areas Mikhail gives focus in his research include tumor suppressors, molecular and cellular biology, anti-cancer therapeutics, cell cycle, and apoptosis among many others. He is currently working as the Professor of Oncology at the Roswell Park Cancer Institute. According to his LinkedIn profile, he was a senior scientist at Ordway Research Institute in Albany before his current position. Mikhail has an excellent educational foundation with a medical degree and a Ph.D. acquired from the First Pavlov State Medical University based in Russia. After finishing his studies, he was employed as an associate lecturer of medicine at New York Medical College where he worked until when he moved to Ordway Research Institute.
Throughout Mr. Blagosklonny professional career, he has devoted his research and experiments on target cancer treatments and anti-aging. He is famous for endorsing Rapamycin to be used to in regulating aging. Target of Rapamycin is a commonly used drug in cancer treatment.
During his research of developing cancer treatments, Mikhail discovered that Rapamycin which is attributed to limit tumor growth could also be used to slow the aging process as well. Mr. Blagosklonny believes in Rapamycin so much that he started using it on himself and he believes that ingesting the drug is safer than overeating, smoking, and driving without a safety belt. Additionally, Rapamycin is also known to work for animals as well as human beings. When tested on animals, it was realized that it could reduce age-related bone loss, chronic inflammation in mice, reversing cardiac aging as well as reversing Alzheimer’s disease.
Mikhail Blagosklonny contributes his knowledge and experience by writing and editing medical journals. In 2010, Mikhail and his colleague at Roswell, Andrei V. Gudkov cofounded the Oncotarget which is an online Peer-reviewed medical journal. The two are also the chief editors who welcome articles from renowned scientists across the globe. Initially, the medical journal was mainly focused on documenting articles on oncology but has since expanded to include other disciplines as well.
Other than that, Mr. Blagosklonny is an associate editor at Cancer Biology & Therapy and sits on the editorial board for Cell Death and Differentiation. Most of Mikhail’s articles include his research on cell cytotherapy, hyperfunction, and chemotherapeutic engineering. He writes articles to inform the public of innovations and technology in the medical field. In total, he has written over 300 research papers and articles and had nearly 270 citations. Mikhail believes that cancer and aging are preventable and treatable and he has the vision of having cancer free and anti-aging society. View his LinkedIn profile